DEN open · 2026
Texture and Color Enhancement Imaging for the Kyoto Classification of Gastritis: Evaluation of Visibility and Color Differences.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oki Shotaro, Takeda Tsutomu, Akazawa Yoichi, Ueyama Hiroya, Ikeda Yuji, Arii Shin, Sai Takeyasu, Uemura Yasuko, Iwano Tomoyo, Yamamoto Momoko, Uchida Ryota, Utsunomiya Hisanori, Suzuki Nobuyuki, Abe Daiki, Ikeda Atsushi, Yatagai Noboru, Matsumoto Kohei, Ueda Kumiko, Hojo Mariko, Nojiri Shuko, Nagahara Akihito
Аннотация
INTRODUCTION: The Kyoto Classification of Gastritis enables endoscopic assessment of Helicobacter pylori (H. pylori) infection status and gastric cancer risk. Initially developed for image-enhanced endoscopy, texture and color enhancement imaging (TXI) allows us to easily distinguish differences in mucosal structure and color. The aim of this study was to evaluate the use of TXI in the visibility of endoscopic findings of gastritis.
METHODS: This was a retrospective analysis using prospectively collected endoscopic data from a prospective, single-center study, in which 220 patients undergoing esophagogastroduodenoscopy were enrolled. Endoscopic images were obtained using both white light imaging (WLI) and TXI (TXI-1 and TXI-2). Ten endoscopists (five experts and five trainees) independently evaluated 52 matched image sets, scoring visibility on a 5-point scale. Inter-rater reliability was assessed using intraclass correlation coefficients. Objective color analysis using the CIE L*a*b* color space and ΔE* values was also performed for map-like redness.
RESULTS: TXI-1 improved visibility for diffuse redness, spotty redness, map-like redness, patchy redness, atrophic border, red streak, and the regular arrangement of collecting venules. Visibility of intestinal metaplasia was also enhanced by TXI-1, although to a lesser extent than other findings. TXI-1 demonstrated "moderate" to "substantial" inter-rater reliability. Objective colorimetric analysis confirmed significantly greater ΔE* values with TXI-1 versus WLI for map-like redness.
CONCLUSION: TXI-1 enhances the visibility of key endoscopic features of H. pylori-associated gastritis. TXI-1 may serve as a useful tool for endoscopic assessment of H. pylori-associated gastritis.
TRIAL REGISTRATION: The study protocol was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN000045323).
METHODS: This was a retrospective analysis using prospectively collected endoscopic data from a prospective, single-center study, in which 220 patients undergoing esophagogastroduodenoscopy were enrolled. Endoscopic images were obtained using both white light imaging (WLI) and TXI (TXI-1 and TXI-2). Ten endoscopists (five experts and five trainees) independently evaluated 52 matched image sets, scoring visibility on a 5-point scale. Inter-rater reliability was assessed using intraclass correlation coefficients. Objective color analysis using the CIE L*a*b* color space and ΔE* values was also performed for map-like redness.
RESULTS: TXI-1 improved visibility for diffuse redness, spotty redness, map-like redness, patchy redness, atrophic border, red streak, and the regular arrangement of collecting venules. Visibility of intestinal metaplasia was also enhanced by TXI-1, although to a lesser extent than other findings. TXI-1 demonstrated "moderate" to "substantial" inter-rater reliability. Objective colorimetric analysis confirmed significantly greater ΔE* values with TXI-1 versus WLI for map-like redness.
CONCLUSION: TXI-1 enhances the visibility of key endoscopic features of H. pylori-associated gastritis. TXI-1 may serve as a useful tool for endoscopic assessment of H. pylori-associated gastritis.
TRIAL REGISTRATION: The study protocol was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN000045323).